Yunju Nam

Dr. Yunju Nam


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YNYunju Nam
Yunju Nam
CKChan Kim
Chan Kim
JHJunghee Han
Junghee Han
SRSeongShick Ryu
SeongShick Ryu
HCHanna Cho
Hanna Cho
TSTaebo Sim
Taebo Sim
C-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4-b]pyridine derivatives and performed SAR studies. We observed that, among these substances, 6r is capable of inhibiting significantly c-KIT and suppressing substantially proliferation of GIST-T1 cancer cells. It is of note that 6r is potent against a c-KIT V560G/D816V double mutant resistant to imatinib. Compared with sunitinib, 6r possesses higher differential cytotoxicity on c-KIT D816V Ba/F3 cells relative to parental Ba/F3 cells. In addition, kinase panel profiling reveals that 6r has reasonable kinase selectivity. It was found that 6r remarkably attenuates proliferation of cancer cells via blockade of c-KIT downstream signaling, and induction of apoptosis and cell cycle arrest. Furthermore, 6r notably suppresses migration and invasion, as well as anchorage-independent growth of GIST-T1 cells. This study provides useful SAR information for the design of novel c-KIT inhibitors overcoming imatinib-resistance.

6 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
YNYunju Nam
Yunju Nam
CKChan Kim
Chan Kim
JHJunghee Han
Junghee Han
SRSeongShick Ryu
SeongShick Ryu
HCHanna Cho
Hanna Cho
TSTaebo Sim
Taebo Sim
The authors would like to make a correction to the previous article